Global Molecular Diagnostics Partnering Deal Terms and Agreements 2014-2020: Access to Headline, Upfront, Milestone and Royalty Data

0 0
Read Time:4 Minute, 4 Second

DUBLIN, Oct. 1, 2020 /PRNewswire/ — The “Global Molecular Diagnostics Partnering Terms and Agreements 2014 to 2020” report has been added to’s offering.

The Global Molecular Diagnostics Partnering Terms and Agreements 2014-2020 report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Molecular Diagnostics agreements announced in the life sciences since 2014.


The report takes the reader through a comprehensive review Molecular Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Molecular Diagnostics partnering deals.

The report presents financial deal term values for Molecular Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Molecular Diagnostics partnering field; both the leading deal values and most active Molecular Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 7650 online deal records of actual Molecular Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type – that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

A comprehensive series of appendices is provided organized by Molecular Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

Report scope

Global Molecular Diagnostics Partnering Terms and Agreements includes:

  • Trends in Molecular Diagnostics dealmaking in the biopharma industry since 2014
  • Analysis of Molecular Diagnostics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Molecular Diagnostics deals
  • Access to Molecular Diagnostics contract documents
  • Leading Molecular Diagnostics deals by value since 2014
  • Most active Molecular Diagnostics dealmakers since 2014

Available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Key Topics Covered:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Molecular Diagnostics dealmaking
2.1. Introduction
2.2. Molecular Diagnostics partnering over the years
2.3. Most active Molecular Diagnostics dealmakers
2.4. Molecular Diagnostics partnering by deal type
2.5. Molecular Diagnostics partnering by therapy area
2.6. Deal terms for Molecular Diagnostics partnering
2.6.1 Molecular Diagnostics partnering headline values
2.6.2 Molecular Diagnostics deal upfront payments
2.6.3 Molecular Diagnostics deal milestone payments
2.6.4 Molecular Diagnostics royalty rates

Chapter 3 – Leading Molecular Diagnostics deals
3.1. Introduction
3.2. Top Molecular Diagnostics deals by value

Chapter 4 – Most active Molecular Diagnostics dealmakers
4.1. Introduction
4.2. Most active Molecular Diagnostics dealmakers
4.3. Most active Molecular Diagnostics partnering company profiles

Chapter 5 – Molecular Diagnostics contracts dealmaking directory
5.1. Introduction
5.2. Molecular Diagnostics contracts dealmaking directory

Chapter 6 – Molecular Diagnostics dealmaking by technology type

Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendix 1 – Molecular Diagnostics deals by company A-Z
Appendix 2 – Molecular Diagnostics deals by stage of development
Phase I
Phase II
Phase III
Appendix 3 – Molecular Diagnostics deals by deal type
Asset purchase
Bigpharma outlicensing
Collaborative R&D
Equity purchase
Joint venture
Material transfer
Spin out
Technology transfer
Appendix 4 – Molecular Diagnostics deals by therapy area
Appendix 5 -Deal type definitions

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:

SOURCE Research and Markets

To Find More Information, Go To Saubio Digital And Look Up Any Topic

About Post Author

Saubio admin

A Saubio member. So SAUBIO stands for GOOD LIFE which is what we all strive for as human beings, for ourselves, our family and our relationships with the people around us and the world we live in.
0 %
0 %
0 %
0 %
0 %
0 %